Introduction: The Medtronic MiniMed 670G insulin pump is the first FDA approved commercial hybrid closed-loop system for pediatric patients with type 1 diabetes (T1D). Clinical trials have shown that the pump’s Auto Mode system effectively maintains blood glucose (BG) levels in target ranges for longer periods of time. Campers may have different insulin requirements than they are accustomed to at home due to the different foods and activity levels at camp. In this retrospective quality review, Medtronic MiniMed 670G pump data from campers attending 2018 ADA Camp MIDICHA were analyzed to investigate the safety and efficacy of campers in AM vs. MM.
Methods: We analyzed de-identified data from 34 campers (mean age 13.1 years [range 8-17]). There were 18 MM and 16 AM campers. BG levels, grams of carbohydrates consumed, and amount of insulin administered were recorded at every meal, evening snack, 12AM, and 2AM. The number of hypoglycemic events (<70 mg/dL), hyperglycemic events (>250 mg/dL), and events within the target BG range (70-250 mg/dL) were also noted.
Results: Our results showed improved glycemic control for campers in AM at breakfast (AM 166.56 mg/dL, MM 182.50 mg/dL), lunch (AM 156.08 mg/dL, MM 167.67 mg/dL), dinner (AM 191.83 mg/dL, MM 194.22 mg/dL), and evening snack (AM 164.13 mg/dL, MM 179.19 mg/dL). Average daily BG was lower for AM (AM 162.12 mg/dL, MM 173.54 mg/dL). The number of hypoglycemic events was 37 for AM and 38 for MM. The number of hyperglycemic events was 62 for AM and 80 for MM.
Discussion: Compared to MM, using the AM system allowed for a higher percentage of BG in the target range and decreased incidences of hypoglycemic and hyperglycemic events. This suggests that the AM system in the Medtronic MiniMed 670G insulin pump can safely and effectively maintain target BG levels for children with T1D in camp settings.
S.H. Chan: None. E.W. Chang: None. J.K. Tang: None. L. Schmeltz: Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk Inc.